Merck Cuts 8 Research, 8 Manufacturing Sites As Part Of Schering Integration
This article was originally published in The Pink Sheet Daily
Executive Summary
With Schering-Plough integration under way, Merck will phase out research and manufacturing operations in effort to achieve $3.5 billion in savings by 2012.
You may also be interested in...
Merck Expands Manufacturing Site In China As Part Of Its Global Restructuring Program
SHANGHAI - Merck announced it would invest $162 million to expand its capacity in China by building a new manufacturing facility, shortly after the company detailed its plans to integrate its R&D, manufacturing and business operations worldwide
Merck's Backbone Is Cardiovascular, Infectious Disease After Pipeline Integration
Merck's late-stage pipeline includes more than 40 compounds in Phase II and Phase III development after combining with Schering-Plough's assets.
Merck/Schering: The Next Wave Of Consolidation
News of Pfizer's takeover of Wyeth has hardly had time to sink in and already a second mega-merger is shaking up big pharma. This time Merck is the buyer; the company announced March 9 that it proposes to acquire its cardiovascular joint venture partner Schering-Plough in a deal valued at $41.1 billion